Amgen (AMGN) Cash & Equivalents (2009 - 2026)

Amgen (AMGN) has reported Cash & Equivalents for 18 consecutive years, with $12.0 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 36.64% year-over-year to $12.0 billion; the TTM figure through Mar 2026 stood at $12.0 billion (up 36.64% YoY), while the FY2025 annual figure was $9.1 billion, down 23.75% from the prior year.
• Cash & Equivalents came in at $12.0 billion for Q1 2026 at Amgen, up from $9.1 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $34.7 billion in Q3 2023, with the low at $5.2 billion in Q2 2022.
• Average Cash & Equivalents over 5 years is $13.4 billion, with a median of $9.4 billion recorded in 2025.
• Across the five-year window, Cash & Equivalents soared 558.24% in 2023 and plunged 74.06% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $7.6 billion in 2022, then soared by 43.45% to $10.9 billion in 2023, then rose by 9.4% to $12.0 billion in 2024, then retreated by 23.75% to $9.1 billion in 2025, then soared by 31.87% to $12.0 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $12.0 billion, $9.1 billion, and $9.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.